COSCIENS Biopharma Inc. announced the appointment of Peter H. Puccetti as Interim Chief Executive Officer, succeeding Anna Biehn. The move is part of the Company’s efforts to reduce costs and align resources with strategic priorities. Puccetti plans to strengthen operational performance and drive shareholder value. COSCIENS focuses on natural ingredients and pharmaceutical solutions, with products like Macimorelin for adult growth hormone deficiency. The Company’s common shares trade on the TSX under “CSCI” and on the US OTC market under “CSCIF”. Investors can find more information on COSCIENS’ website.

Read more at GlobeNewswire.: COSCIENS Biopharma Inc. Announces Leadership Change